Spectranetics' Extreme 0.9mm catheter gains PMA supplement:
This article was originally published in Clinica
Spectranetics has obtained FDA approval for its application to market the Extreme 0.9mm disposable catheter for laser coronary angioplasty. The catheter is designed to remove blockages in small coronary vessels that are hard to reach. The company of Colorado Springs, Colorado, plans only a limited release of the product in the two months before a full launch in October.
You may also be interested in...
Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.
Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.